Furthermore , this therapy could increase the dem and on radiation re sources .
There is no evidence on which to make a recommendation for patients with node-negative tumours that have not penetrated the muscularis propria .
For patients unable to undergo radiation , adjuvant chemotherapy alone may be of benefit , particularly for those with lymph-node metastases .
There is insufficient evidence from r and omized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer ( T1 - 4 , N1 - 2 , M0 ) .
OPTIONS Neoadjuvant or adjuvant treatments compared with " curative " surgery alone .
OUTCOMES Overall survival , disease-free survival , and adverse effects .
The radiation fields used can possibly damage the left kidney , result ing in hypertension and other renal problems .
Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients.
In order to evaluate the results on successful adjuvant chemotherapy in resected gastric cancer we performed a r and omised trial on 134 patients in two arms : a control one with no further treatment after surgery versus a treatment arm given mitomycin-C ( MMC ) , 20 mg/m2 intravenously one day every 6 weeks for four courses , starting before the sixth week after surgery . The median follow-up was 105 months . In the control arm , 49 out of 66 patients died due to recurrence , versus 40 out of 68 patients in treatment arm .  Actuarial survival curve was statistically significant ( P < 0.025 ) in favour of the treatment group . Liver metastases were lower in adjuvant group than in the control group ( 8/68 versus 19/66 ) . Toxicity was mild . Main toxic effects were thrombocytopenia , leukopenia , nausea and vomiting . A pelvis renal cancer as a second malignancy 8 years after gastric cancer was observed . In that particular case MMC was given after surgery . We conclude that adjuvant chemotherapy based on MMC given in the early period after surgery , improves survival rate in gastric cancer resected patients
Furthermore , this therapy could increase the dem and on radiation re sources .
There is no evidence on which to make a recommendation for patients with node-negative tumours that have not penetrated the muscularis propria .
For patients unable to undergo radiation , adjuvant chemotherapy alone may be of benefit , particularly for those with lymph-node metastases .
There is insufficient evidence from r and omized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer ( T1 - 4 , N1 - 2 , M0 ) .
OPTIONS Neoadjuvant or adjuvant treatments compared with " curative " surgery alone .
OUTCOMES Overall survival , disease-free survival , and adverse effects .
The radiation fields used can possibly damage the left kidney , result ing in hypertension and other renal problems .